Milestone Pharmaceuticals Inc
MIST2.070USD
-0.080-3.72%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
176.30MMarket Cap
LossP/E TTM
More Details of Milestone Pharmaceuticals Inc Company
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.
Milestone Pharmaceuticals Inc Info
Ticker SymbolMIST
Company nameMilestone Pharmaceuticals Inc
IPO dateMay 09, 2019
CEOOliveto (Joseph)
Number of employees33
Security typeOrdinary Share
Fiscal year-endMay 09
Address420-1111 boul. Dr.-Frederik-Philips
CityMONTREAL
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryCanada
Postal codeH4M 2X6
Phone15143360444
Websitehttps://www.milestonepharma.com
Ticker SymbolMIST
IPO dateMay 09, 2019
CEOOliveto (Joseph)
Company Executives of Milestone Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. David Bharucha
Dr. David Bharucha
Chief Medical Officer
Chief Medical Officer
78.45K
+212.30%
Mr. Amit Hasija
Mr. Amit Hasija
Chief Financial Officer, Executive Vice President - Corporate Development
Chief Financial Officer, Executive Vice President - Corporate Development
69.20K
+260.35%
Dr. Robert James Wills, Ph.D.
Dr. Robert James Wills, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
65.00K
+333.33%
Mr. Michael John Tomsicek
Mr. Michael John Tomsicek
Independent Director
Independent Director
15.00K
--
Mr. Stuart Duty
Mr. Stuart Duty
Independent Director
Independent Director
--
--
Mr. Joeseph C. Papa
Mr. Joeseph C. Papa
Independent Director
Independent Director
--
--
Mr. Andrew Saik
Mr. Andrew Saik
Independent Director
Independent Director
--
--
Ms. Lisa M. Giles
Ms. Lisa M. Giles
Independent Director
Independent Director
--
--
Mr. Joseph Oliveto
Mr. Joseph Oliveto
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Lorenz Muller
Mr. Lorenz Muller
Chief Commercial Officer
Chief Commercial Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. David Bharucha
Dr. David Bharucha
Chief Medical Officer
Chief Medical Officer
78.45K
+212.30%
Mr. Amit Hasija
Mr. Amit Hasija
Chief Financial Officer, Executive Vice President - Corporate Development
Chief Financial Officer, Executive Vice President - Corporate Development
69.20K
+260.35%
Dr. Robert James Wills, Ph.D.
Dr. Robert James Wills, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
65.00K
+333.33%
Mr. Michael John Tomsicek
Mr. Michael John Tomsicek
Independent Director
Independent Director
15.00K
--
Mr. Stuart Duty
Mr. Stuart Duty
Independent Director
Independent Director
--
--
Mr. Joeseph C. Papa
Mr. Joeseph C. Papa
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Simplify Asset Management Inc
9.34%
Adage Capital Management, L.P.
8.19%
Trails Edge Capital Partners LP
4.50%
OrbiMed Advisors, LLC
3.78%
Morgan Stanley & Co. LLC
3.09%
Other
71.09%
Shareholders
Shareholders
Proportion
Simplify Asset Management Inc
9.34%
Adage Capital Management, L.P.
8.19%
Trails Edge Capital Partners LP
4.50%
OrbiMed Advisors, LLC
3.78%
Morgan Stanley & Co. LLC
3.09%
Other
71.09%
Shareholder Types
Shareholders
Proportion
Investment Advisor
16.23%
Hedge Fund
14.25%
Research Firm
5.04%
Investment Advisor/Hedge Fund
3.94%
Private Equity
3.78%
Individual Investor
3.57%
Venture Capital
1.22%
Family Office
1.17%
Bank and Trust
0.02%
Other
50.77%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
99
19.38M
22.80%
-5.64M
2025Q2
99
14.54M
18.86%
-15.65M
2025Q1
102
12.26M
22.94%
-17.24M
2024Q4
99
25.17M
47.19%
-9.38M
2024Q3
113
29.31M
55.02%
-13.44M
2024Q2
115
30.81M
57.87%
-11.80M
2024Q1
116
31.96M
60.43%
+3.19M
2023Q4
112
18.49M
55.02%
-13.59M
2023Q3
109
20.24M
60.32%
-12.06M
2023Q2
108
21.35M
63.87%
-11.78M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Simplify Asset Management Inc
990.00K
1.16%
+140.00K
+16.47%
Jun 30, 2025
Trails Edge Capital Partners LP
5.33M
6.27%
+5.33M
--
Jul 14, 2025
Morgan Stanley & Co. LLC
817.82K
0.96%
-148.10K
-15.33%
Jun 30, 2025
Oliveto (Joseph Gerard)
2.51M
2.95%
+66.67K
+2.73%
Jul 11, 2025
RTW Investments L.P.
2.51M
2.95%
--
--
Jun 30, 2025
Propel Bio Management, LLC
1.79M
2.11%
+340.00K
+23.42%
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
Simplify Propel Opportunities ETF
8.04%
SPDR S&P International Small Cap ETF
0.01%
Avantis US Small Cap Equity ETF
0%
Simplify Propel Opportunities ETF
Proportion8.04%
SPDR S&P International Small Cap ETF
Proportion0.01%
Avantis US Small Cap Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Milestone Pharmaceuticals Inc?
The top five shareholders of Milestone Pharmaceuticals Inc are:
Simplify Asset Management Inc holds 990.00K shares, accounting for 1.16% of the total shares.
Trails Edge Capital Partners LP holds 5.33M shares, accounting for 6.27% of the total shares.
Morgan Stanley & Co. LLC holds 817.82K shares, accounting for 0.96% of the total shares.
Oliveto (Joseph Gerard) holds 2.51M shares, accounting for 2.95% of the total shares.
RTW Investments L.P. holds 2.51M shares, accounting for 2.95% of the total shares.
Simplify Asset Management Inc holds 990.00K shares, accounting for 1.16% of the total shares.
Trails Edge Capital Partners LP holds 5.33M shares, accounting for 6.27% of the total shares.
Morgan Stanley & Co. LLC holds 817.82K shares, accounting for 0.96% of the total shares.
Oliveto (Joseph Gerard) holds 2.51M shares, accounting for 2.95% of the total shares.
RTW Investments L.P. holds 2.51M shares, accounting for 2.95% of the total shares.
What are the top three shareholder types of Milestone Pharmaceuticals Inc?
The top three shareholder types of Milestone Pharmaceuticals Inc are:
Simplify Asset Management Inc
Adage Capital Management, L.P.
Trails Edge Capital Partners LP
Simplify Asset Management Inc
Adage Capital Management, L.P.
Trails Edge Capital Partners LP
How many institutions hold shares of Milestone Pharmaceuticals Inc (MIST)?
As of 2025Q3, 99 institutions hold shares of Milestone Pharmaceuticals Inc, with a combined market value of approximately 19.38M, accounting for 22.80% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 3.94%.
What is the biggest source of revenue for Milestone Pharmaceuticals Inc?
In --, the -- business generated the highest revenue for Milestone Pharmaceuticals Inc, amounting to -- and accounting for --% of total revenue.
